MedPharm accelerates strategy to broaden service offering into commercial manufacturing

MedPharm has announced two new appointments to its board to support plans to grow its commercial manufacturing services

The new members, Paul Johnson and Norman Barras, will be joining MedPharm’s board following a rigorous search, aimed at deepening the company’s expertise in pharmaceutical development and manufacturing services.

Performance tests are an integral part of any formulation development programme at MedPharm.

They are used strategically throughout the development process to mitigate development risks and failures due to inadequate product performance. MedPharm’s proven and unique models derisk the development process and greatly increase the probability of success.

“MedPharm has a clear strategy to broaden its services, particularly into the later stage development and commercial manufacturing of topical products,” stated President & CEO Eugene Ciolfi.

"Paul and Norman bring a wealth of experience, which will be highly beneficial to MedPharm as we expand our services offerings. Their deep understanding of integrating pharmaceutical operations, including commercial manufacture, will be invaluable to the business as we expand into these new markets."

Paul Johnson is an Operating Partner with Ampersand Capital, which made a strategic investment in MedPharm in early 2018. Paul previously served as President and CEO of DPT and Renaissance Pharmaceuticals, a leading, high growth, topicals CDMO and specialty generics company, which was sold to Mylan in 2016. He has over 30 years of broad and diverse experience in the pharmaceutical industry.

Norman Barras is an independent consultant with an extensive career in pharmaceutical research, contract manufacturing and development, which included senior leadership roles at Patheon, Penn/PCI Pharmaceuticals and Lonza Biologics. He has more than 30 years of experience in the pharmaceutical industry.

Companies